ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 167 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2020. The put-call ratio across all filers is 1.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $1,025,000 | -42.2% | 17,182 | -64.5% | 0.03% | -34.9% |
| Q3 2019 | $1,773,000 | -20.0% | 48,352 | +1.5% | 0.04% | -10.4% |
| Q2 2019 | $2,215,000 | +105.1% | 47,615 | +102.9% | 0.05% | +71.4% |
| Q4 2018 | $1,080,000 | +122.7% | 23,472 | +117.4% | 0.03% | +180.0% |
| Q3 2018 | $485,000 | -39.3% | 10,796 | -2.3% | 0.01% | -41.2% |
| Q1 2018 | $799,000 | +11.7% | 11,046 | -22.8% | 0.02% | +21.4% |
| Q3 2017 | $715,000 | -19.7% | 14,309 | -43.2% | 0.01% | -36.4% |
| Q1 2017 | $890,000 | +139.9% | 25,211 | -15.0% | 0.02% | +69.2% |
| Q4 2016 | $371,000 | -59.4% | 29,651 | -55.0% | 0.01% | -53.6% |
| Q3 2016 | $913,000 | -61.0% | 65,941 | -72.2% | 0.03% | -63.6% |
| Q2 2016 | $2,341,000 | -50.6% | 236,943 | -15.5% | 0.08% | -43.4% |
| Q1 2016 | $4,741,000 | +34.3% | 280,342 | +80.8% | 0.14% | +63.9% |
| Q4 2015 | $3,530,000 | – | 155,077 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |